Vonoprazan continued to be noninferior in maintenance of healing at 24 weeks for both the 10 mg (89.2%) and 20 mg (90.7%) doses versus lansoprazole (79.7%).

Among those on vonoprazan throughout the study, mean percentages of 24-hour heartburn-free days were 62.6% for the 10 mg dose (n = 247), and 60.7% for the 20 mg dose (n = 235).

The FDA approved vonoprazan (Voquezna) for all grades of erosive gastroesophageal reflux disease (GERD) and heartburn relief associated with the condition, Phathom Pharmaceuticals announced on ...

Phathom Pharmaceuticals announces vonoprazan NDA submission for non-erosive GERD. News release. Phathom Pharmaceuticals. September 26, 2023. Accessed December 6, 2023.

The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial.

Vonoprazan was noninferior to high-dose IV proton pump inhibitor therapy in preventing 30-day rebleeding among patients with high-risk peptic ulcer bleeding who had achieved endoscopic hemostasis ...

Vonoprazan will be made available in 10mg and 20mg strengths. A potassium-competitive acid blocker (P-CAB), the drug differs from traditional acid suppressants such as proton pump inhibitors by ...